Sakar Healthcare has signed its 40th agreement with Zydus Lifesciences to supply oncology products in the GCC (Gulf Cooperation Council) and other emerging markets. This milestone marks the company's 40th agreement involving anti-cancer products globally, underscoring its expanding commercial reach in high-value therapeutic segments.

Partnership Milestone With Zydus Lifesciences

The latest agreement with Zydus Lifesciences highlights the depth of the collaboration between the two entities. The deal is specifically directed at oncology products, targeting the GCC region and broader emerging markets. This positions Sakar Healthcare as a key supply and development partner in these geographies.

Regulatory Progress In The European Union

Sakar Healthcare has advanced its regulatory footprint in the European Union with 23 Marketing Authorization (MA) filings. Of these, 5 MAs have been secured from 8 filings made by a partner in Bulgaria, while the company has applied for 13 own MAs in the Czech Republic, Croatia, and Poland. Additionally, the company has submitted 33 site variations across the EU, covering 18 cytotoxic molecules in countries including Germany, Italy, and the UK. To date, 5 site variation approvals have been received, comprising 3 by the EMA (EU) and 2 by the MHRA (UK).

In-House API Development And Backward Integration

A central pillar of Sakar Healthcare's strategy is backward integration through in-house API development. The company has developed 21 APIs, including 16 with Written Confirmation and 2 CEP approvals already secured. This capability enhances control over the supply chain and quality standards, reducing dependency on external suppliers and strengthening competitive positioning in regulated markets.

These developments reflect a transition towards a more integrated, regulatory-led business model. With a strengthening pipeline of approvals and increasing integration across the value chain, Sakar Healthcare aims to accelerate growth and expand market share in the coming years.

Sakar Healthcare Limited has intimated the stock exchanges of the resignation of its Secretarial Auditors, M/s. Nishant Pandya & Associates, Practising Company Secretaries, with immediate effect from the Financial Year 2025-26 onwards. The resignation letter, dated 6th May, 2026, was submitted by the firm citing personal reasons. The company made this disclosure in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III of the Listing Regulations and relevant SEBI Circulars.

Resignation Details

M/s. Nishant Pandya & Associates, bearing Membership No. ACS-51005 and COP No. 22435, informed the Board of Directors of Sakar Healthcare that they are no longer associated with the company as Secretarial Auditors for the financial year 2025-26. The firm explicitly stated that there are no other material reasons for the resignation and raised no objection to the appointment of any other Secretarial Auditor by the company.

The key details of the disclosure, as submitted under Annexure 1 in compliance with Regulation 30, are outlined below:

Regulatory Compliance

The intimation was signed and submitted by Bharat Soni, Company Secretary and Compliance Officer of Sakar Healthcare Limited, on 6th May, 2026. The disclosure was addressed to the National Stock Exchange of India Limited in accordance with the applicable listing regulations. The company has requested the exchange to take note of the development in its records.